Cancer Drugs Speed to Accelerated Approvals, Then Hit the Brakes in Timely, Clinically Beneficial Confirmatory Trials
Whither CAR T? Will the FDA Being Under the Hood and the Availability of Bispecifics Make These Therapies Less Attractive?
